查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014824

腹腔內感染疾病市場：依抗生素類型、感染疾病類型、病原體類型和最終用戶分類－2026-2032年全球市場預測

Intra-abdominal Infections Market by Antibiotic Class, Infection Type, Pathogen Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腹腔內感染疾病市場價值將達到 266.6 億美元，到 2026 年將成長至 289.3 億美元，到 2032 年將達到 497 億美元，年複合成長率為 9.30%。

主要市場統計數據
基準年 2025 266.6億美元
預計年份：2026年 289.3億美元
預測年份 2032 497億美元
複合年成長率 (%) 9.30%

腹腔內感染疾病（IVF）是一組異質性疾病，從簡單的局部發炎到複雜的、危及生命的多重細菌感染性敗血症均有涉及。臨床醫生會遇到社區型感染和院內感染的混合病例，這些病例的差異取決於感染源、宿主因素和微生物學特徵。因此，儘管早期識別和快速控制感染源仍然是有效治療的關鍵，但抗生素的選擇需要在廣泛的經驗性治療和基於培養和藥敏試驗結果逐步減量之間取得平衡。

診斷的複雜性源自於臨床症狀的重疊、培養陽性率的差異以及不斷變化的抗藥性模式。影像學檢查、手術評估和腹腔內培養固然至關重要，但每種方法都存在局限性，會影響治療時機的選擇。同時，主要病原體的抗生素抗藥性正在改變經驗性治療流程，導致重症病例更依賴高劑量藥物和聯合治療。這些變化進一步凸顯了協作合理使用抗生素、建立多學科診療路徑以及加強醫院監測的必要性，以維持治療選擇並最佳化治療效果。

因此，臨床、營運和商業領域的相關人員必須就優先事項達成共識，包括快速診斷、綜合管理和供應鏈連續性。了解影響治療決策的細微臨床差異和系統性壓力，將有助於領導者更好地設計干預措施，從而降低發病率、縮短住院時間並減少不必要的頻譜抗生素暴露的副作用。

快速變革正在重塑腹腔內感染疾病管理的臨床實踐、診斷和供應動態。

腹腔內感染疾病的治療格局正經歷著快速而深刻的變革，其驅動力包括抗生素抗藥性的出現、技術的進步以及醫療服務模式的轉變。抗藥性細菌的流行趨勢正在重塑經驗性用藥模式，提升了對多重抗藥性革蘭氏陰性菌仍然有效的藥物的臨床和經濟價值。同時，快速診斷和分子病原體檢測技術的創新正在縮短從患者就診到開始標靶治療的時間，從而能夠在適當情況下更快地逐步減少治療劑量，並減少不必要的頻譜抗生素暴露。

預計 2025 年美國關稅調整對抗生素供應鏈、醫院採購慣例和臨床實踐的影響。

貿易和關稅政策環境會對抗生素、生產原料以及治療腹腔內感染疾病所需的醫療用品的成本結構和供應產生重大影響。進口關稅和貿易壁壘的變化會改變活性成分和製劑的生產成本，進而影響醫院和批發商的籌資策略。實際上，如果關稅造成的供應鏈中斷，採購負責人可能會發現，某些靜脈注射抗生素和腸外製劑的供應商選擇範圍縮小、前置作業時間延長，採購成本也更高。

涵蓋抗生素分類、感染疾病的臨床特徵、病原體概況、年齡層和醫療保健環境的細分市場臨床和商業性見解。

精細的細分觀點揭示了治療方法方案、感染疾病趨勢、病原體特徵、患者人口統計特徵以及醫療環境如何相互交織，共同塑造臨床和商業性趨勢。就抗生素類型而言，臨床醫生主要依賴碳青黴烯類、頭孢菌素類和青黴素類來涵蓋頻譜腹腔內病原體。在碳青黴烯類藥物中，多利培南、厄他培南、Imipenem/西司他丁和美Meropenem等藥物的選擇取決於疑似病原體、組織穿透需求和抗藥性模式。在頭孢菌素類藥物的使用方面，第三代頭孢菌素（如頭孢噻肟和頭孢曲松）與第四代頭孢菌素（如頭孢吡肟）有所區別，每種藥物的選擇都基於其對特定革蘭氏陰性菌的覆蓋範圍，並在必要時考慮其對中樞神經系統的穿透性。青黴素聯合治療，包括Ampicillin/舒巴坦和哌拉西林/他唑巴坦，在社區獲得性多重細菌感染疾病中繼續發揮重要作用，並且在許多醫療機構的治療方案中作為經驗性治療方案。

美洲、歐洲、中東、非洲和亞太地區的治療模式、供應鏈韌性和政策方面的區域差異，影響著臨床反應。

區域差異對臨床實務、供應鏈物流和政策環境有顯著影響，進而影響醫療服務提供者和系統應對腹腔內感染疾病的方式。在美洲，實證經驗選擇和在高級醫療機構中整合快速診斷技術日益受到重視，並被納入治療方案和合理用藥框架；同時，供應鏈整合和聯合採購組織正在影響處方藥清單的製定和價格談判。這些趨勢正在促進臨床領導者和採購部門之間的合作，以確保關鍵藥物的穩定供應。

一個競爭與合作並存的企業環境，專注於製造能力、診斷技術創新以及抗感染疾病療法的策略合作。

腹腔感染疾病治療方法和服務領域的競爭格局呈現出多元化的特點，既有成熟的製藥公司，也契約製造生產商、診斷技術創新者和臨床服務提供者。成熟的製藥公司通常致力於維持可靠的供應鏈、延長產品生命週期，並透過教育和處方集支持藥物舉措措施。契約製造生產商和無菌注射劑生產廠在確保腸外抗生素供應方面發揮著至關重要的作用，這為策略夥伴關係和產能投資創造了機會。

為醫療保健領導者提供可操作且優先考慮的建議，以改善臨床結果、維持治療選擇並增強供應韌性。

醫療衛生領導者應採取一系列切實可行的優先措施，以改善臨床療效、保障治療可近性並降低供應風險。首先，他們應協調採購和臨床治理，並透過定期進行跨部門的處方集選擇、庫存管治和臨床可接受的替代療法審查，確保在供應波動的情況下也能維持治療的連續性。其次，他們應加快引入快速診斷工具，並將清晰的治療分期方案納入臨床路徑，以便在適當情況下快速縮小經驗性頻譜療法的範圍，降低抗藥性細菌的選擇壓力，並保護一流藥物。

採用穩健的混合方法研究方法，整合原始臨床數據、真實世界運作數據和嚴格的二手證據，以確保可靠性。

本執行摘要依據的研究採用混合方法，整合了原始臨床數據、站點層面的營運數據和全面的二手研究，以得出可靠且具有現實意義的結論。原始數據透過與外科、重症監護、感染疾病和藥房的臨床醫生進行結構化訪談和諮詢會議收集，並輔以採購和供應鏈專家的意見，以反映實際運作。這些一線觀點體現在藥物選擇、合理用藥實務和供應鏈緊急應變計畫等情境的建構中。

整合策略重點，突顯臨床需求、營運風險和整體系統改進的機會。

本執行摘要重點闡述了三大優先事項之間的相互關聯：確保獲得有效抗生素、加快基於診斷的治療以及增強系統應對供應和政策波動的能力。臨床上，需求顯而易見：迅速控制感染源和以患者為中心的抗生素治療能夠挽救生命，但要持續實現這一目標，需要投資於診斷和合理用藥基礎設施以及跨學科合作。在營運方面，採購和藥房負責人必須預見供應鏈中斷，並保持靈活的策略，以確保關鍵藥物的供應，同時不降低臨床標準。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依抗生素類型分類的腹腔內感染疾病市場

  • 碳青黴烯類
    • 多利培南
    • 艾爾他培南
    • Imipenem/西司他丁
    • Meropenem
  • 頭孢菌素
    • 第四代
    • 第三代
      • 頭孢噻肟
      • 頭孢曲松
  • 青黴素類
    • Ampicillin/舒巴坦
    • 哌拉西林/他唑巴坦

第9章 腹腔內感染疾病依類型分類的市場感染疾病

  • 社區傳播
    • 併發症
    • 非併發症
  • 院內感染
    • ICU相關
    • 術後

第10章 依病原體分類的腹腔內感染疾病市場

  • 厭氧菌
    • 脆弱擬桿菌
    • 梭菌屬
  • 革蘭氏陰性菌
    • 腸桿菌科
    • 銅綠假單胞菌
  • 革蘭氏陽性菌
    • 腸球菌屬
    • 金黃色葡萄球菌

第11章 腹腔內感染疾病市場：依最終用戶分類

  • 門診部
  • 醫院
    • 二級醫療保健
    • 三級醫療保健

第12章 腹腔內感染疾病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 腹腔內感染疾病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 腹腔內感染疾病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腹腔內感染疾病市場

第16章 中國腹腔內感染疾病市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-43127F7279D5

The Intra-abdominal Infections Market was valued at USD 26.66 billion in 2025 and is projected to grow to USD 28.93 billion in 2026, with a CAGR of 9.30%, reaching USD 49.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.66 billion
Estimated Year [2026] USD 28.93 billion
Forecast Year [2032] USD 49.70 billion
CAGR (%) 9.30%

Intra-abdominal infections represent a heterogeneous group of conditions that span simple localized inflammatory processes to complex, life-threatening polymicrobial sepsis. Clinicians confront a mix of community-acquired and hospital-acquired presentations that vary by source, host factors, and microbiology. As a result, early recognition and rapid source control remain the cornerstones of effective management, while antimicrobial selection must balance empiric breadth with de-escalation guided by culture and sensitivity data.

Diagnostic complexity stems from overlapping clinical presentations, variable culture yields, and evolving resistance patterns. Imaging, surgical assessment, and peritoneal cultures are critical, yet each has limitations that influence therapeutic timing. Concurrently, antimicrobial resistance among key pathogens has altered empirical therapy algorithms, prompting greater reliance on higher-tier agents and combination regimens in severe cases. These changes amplify the need for coordinated antimicrobial stewardship, multidisciplinary care pathways, and robust hospital surveillance to preserve therapeutic options and optimize outcomes.

Stakeholders across clinical, operational, and commercial domains must therefore align on priorities that include timely diagnostics, stewardship integration, and supply chain continuity. By understanding the clinical nuances and system pressures that drive treatment decisions, leaders can better design interventions that reduce morbidity, shorten hospital stays, and limit the collateral harm of unnecessary broad-spectrum antibiotic exposure.

Rapid Transformations Reshaping Clinical Practice, Diagnostics, and Supply Dynamics in Intra-abdominal Infection Management

The landscape of intra-abdominal infection management is undergoing rapid and consequential shifts driven by antimicrobial resistance, technological advances, and changes in care delivery models. Resistance trends are reshaping empiric prescribing patterns and elevating the clinical and economic value of agents with retained activity against multidrug-resistant Gram-negative organisms. Simultaneously, innovations in rapid diagnostics and molecular pathogen detection are beginning to shorten the interval between presentation and targeted therapy, enabling faster de-escalation when appropriate and reducing unnecessary exposure to broad-spectrum agents.

Care delivery transformations are equally impactful. Growth in ambulatory surgical centers and shifts toward earlier discharge and outpatient parenteral antimicrobial therapy have altered patient flows and medication utilization, requiring new coordination between inpatient teams and community providers. These transitions are compounded by evolving regulatory expectations for stewardship and reporting, which place a premium on measurable metrics and program accountability. As a result, stakeholders face a landscape where clinical efficacy, supply reliability, and stewardship compliance converge to determine both patient outcomes and organizational risk.

Taken together, these forces demand adaptive strategies that integrate novel diagnostics, stewardship protocols, and supply chain resilience while maintaining clinician autonomy in critical decision moments. Organizations that proactively align clinical pathways, procurement practices, and surveillance capabilities will be better positioned to manage complexity and sustain therapeutic options over the long term.

Anticipated Effects of United States Tariff Adjustments on Antibiotic Supply Chains, Hospital Procurement Practices, and Clinical Access in 2025

The policy environment surrounding trade and tariffs can materially influence the cost structure and availability of antimicrobial agents, manufacturing inputs, and medical supplies integral to intra-abdominal infection care. Changes to import duties and trade barriers alter manufacturing economics for active pharmaceutical ingredients and finished dosage forms, which in turn affect procurement strategies for hospitals and distributors. In practical terms, procurement teams may experience narrower supplier options, increased lead times, and higher acquisition costs for select intravenous antibiotics and parenteral formulations when tariffs disrupt established supply chains.

Clinicians and pharmacy leaders should anticipate secondary effects that manifest as alterations in hospital formularies and therapeutic guidelines. When sourcing constraints or price pressures exist, hospitals commonly reassess formulary inclusions and may substitute clinically equivalent agents or adjust stewardship policies to preserve critical stock. These operational responses require clear clinical governance to prevent unintended consequences such as suboptimal empiric coverage or inappropriate substitution in high-risk patients.

Moreover, manufacturers and contract manufacturers may respond to tariff-driven margin pressures by relocating production, redesigning supply agreements, or accelerating investments in regional manufacturing to mitigate exposure. Such strategic adaptations can improve long-term resilience but create short-term volatility. Therefore, cross-functional planning that combines procurement forecasting, inventory buffering, and continual clinical oversight is essential to maintain access and clinical integrity in the face of tariff-induced supply chain disruption.

Segment-Level Clinical and Commercial Insights Spanning Antibiotic Classes, Infection Presentations, Pathogen Profiles, Age Cohorts, and Healthcare Settings

A nuanced segmentation lens reveals how therapeutic choices, infection contexts, pathogen profiles, patient demographics, and care settings intersect to shape clinical and commercial dynamics. By antibiotic class, clinicians rely on carbapenems, cephalosporins, and penicillins to cover the broad spectrum of intra-abdominal pathogens. Within carbapenems, agents such as doripenem, ertapenem, imipenem/cilastatin, and meropenem are deployed based on pathogen suspicion, tissue penetration requirements, and resistance patterns. Cephalosporin use differentiates between third-generation options like cefotaxime and ceftriaxone and fourth-generation cefepime, each selected for specific Gram-negative coverage and central nervous system penetration when indicated. Penicillin-based combinations, including ampicillin/sulbactam and piperacillin/tazobactam, retain an important role for community-acquired polymicrobial infections and as empiric therapy in many institutional protocols.

Infection type segmentation between community-acquired and hospital-acquired presentations changes therapeutic imperatives. Community-acquired cases, subdivided into complicated and uncomplicated forms, often permit narrower empiric coverage when patients present without recent healthcare exposure. Conversely, hospital-acquired infections, whether associated with ICU care or post-surgical settings, demand broader empiric regimens because of increased risk of multidrug-resistant organisms. Pathogen-driven insight distinguishes anaerobic organisms such as Bacteroides fragilis and Clostridium species from Gram-negative pathogens including Enterobacteriaceae and Pseudomonas aeruginosa, and from Gram-positive agents like Enterococcus species and Staphylococcus aureus, each of which drives different empiric and definitive therapy choices and stewardship challenges.

Patient age group further modulates therapeutic decisions, as adult, geriatric, and pediatric populations present distinct pharmacokinetic and safety considerations that affect dosing, formulation selection, and monitoring. Finally, end user segmentation between ambulatory care centres and hospitals, with hospitals split into secondary and tertiary care, determines resource availability, access to advanced diagnostics, and procedural capabilities for source control. Collectively, these intersecting segments demand tailored clinical pathways, procurement strategies, and education programs to ensure that each patient cohort receives optimal, context-appropriate care.

Regional Treatment Patterns, Supply Chain Resilience, and Policy Variations Shaping Clinical Responses Across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional variation exerts a profound influence on clinical practice, supply chain logistics, and policy environments, shaping how providers and health systems approach intra-abdominal infections. In the Americas, treatment protocols and stewardship frameworks increasingly emphasize evidence-based empiric selection and the integration of rapid diagnostics in high-acuity centers, while supply chain consolidation and group purchasing organizations influence formulary decisions and pricing negotiations. These dynamics encourage coordination between clinical leaders and procurement to ensure consistent access to critical agents.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure, regulatory oversight, and antimicrobial resistance profiles creates divergent priorities. High-resource centers may focus on rapid molecular diagnostics and advanced stewardship programs, whereas resource-constrained settings prioritize access to essential antibiotics, basic imaging, and surgical capacity. Policy-level interventions and regional collaborations play a larger role in supporting antimicrobial stewardship and addressing resistance surveillance in this diverse region.

Asia-Pacific presents a combination of high-volume clinical demand, rapid technological adoption, and varied domestic manufacturing capacity. Regional manufacturers can mitigate some supply disruptions, but demand pressures and resistance trends necessitate coordinated national strategies for stewardship and procurement. Across all regions, the interplay between regulation, manufacturing geography, and clinical practice determines both short-term operational choices and long-term resilience of supply and therapeutic options.

Competitive and Collaborative Company Landscape Highlighting Manufacturing Capacity, Diagnostic Innovation, and Strategic Partnerships in Anti-infective Care

The competitive landscape for therapies and services relevant to intra-abdominal infections is characterized by a mix of established pharmaceutical manufacturers, contract producers, diagnostic innovators, and clinical service providers. Established drug producers often focus on maintaining reliable supply lines, extending product lifecycles, and supporting stewardship initiatives through education and formulary support. Contract manufacturers and specialized sterile injectable plants play a pivotal role in ensuring availability of parenteral antibiotics, creating opportunities for strategic partnerships and capacity investments.

Diagnostic companies and hospital laboratory networks are increasingly influential, as rapid identification technologies and susceptibility platforms directly change prescribing behavior and reduce time to optimal therapy. Collaboration between diagnostic vendors and clinical leaders can yield pathway-level improvements that reduce inappropriate broad-spectrum use and speed targeted therapy. Additionally, service providers that support outpatient parenteral antimicrobial therapy and post-discharge monitoring are expanding the continuum of care, enabling earlier transition from inpatient settings without sacrificing safety.

Strategic alliances between pharmaceutical manufacturers, diagnostic firms, and healthcare systems can create integrated offerings that pair reliable antimicrobial supply with diagnostic stewardship. Such collaboration also supports joint efforts to address antimicrobial resistance through data sharing, formulary optimization, and targeted education for prescribers and care teams.

Actionable and Prioritized Recommendations for Healthcare Leaders to Improve Clinical Outcomes, Preserve Therapeutic Options, and Strengthen Supply Resilience

Healthcare leaders should adopt a set of practical, prioritized actions to strengthen clinical outcomes, maintain therapeutic access, and mitigate supply risks. First, align procurement and clinical governance by instituting regular cross-functional reviews of formulary choices, inventory exposure, and clinically acceptable therapeutic alternatives to ensure continuity in the face of supply variability. Second, accelerate adoption of rapid diagnostic tools and embed explicit de-escalation protocols into care pathways so that empiric broad-spectrum therapy is narrowed promptly when appropriate, reducing resistance selection pressure and conserving higher-tier agents.

Third, expand outpatient parenteral antimicrobial therapy frameworks and strengthen discharge coordination to reduce inpatient length of stay while maintaining safety. Fourth, implement tiered stewardship metrics that account for infection type, pathogen risk, and patient age to target education and audit efforts where they will have the greatest clinical impact. Fifth, engage manufacturers and contract manufacturers proactively through multi-year agreements, dual-sourcing where feasible, and contingency planning to alleviate tariff- or disruption-related scarcity. Finally, invest in workforce training that equips surgical teams, intensivists, pharmacists, and infectious disease specialists with the skills to execute rapid source control, optimized dosing, and coordinated follow-up care.

Taken together, these actions balance immediate operational resilience with long-term stewardship objectives, positioning organizations to deliver high-quality care while preserving therapeutic effectiveness.

Robust Mixed Methods Research Approach Integrating Primary Clinical Input, Real-world Operational Data, and Rigorous Secondary Evidence for Reliability

The research underpinning this executive summary uses a mixed-methods approach that integrates primary clinical inputs, facility-level operational data, and comprehensive secondary research to ensure robust, context-sensitive conclusions. Primary inputs were gathered through structured interviews and advisory discussions with clinicians across surgical, critical care, infectious disease, and pharmacy disciplines, complemented by procurement and supply chain professionals to capture operational realities. These firsthand perspectives informed scenario building around drug selection, stewardship practices, and supply contingencies.

Secondary research synthesized peer-reviewed literature, clinical guidelines, regulatory documents, and publicly available surveillance data from health authorities to ground findings in established evidence. Real-world data sources such as hospital utilization patterns, antimicrobial consumption records, and laboratory susceptibility reports were analyzed to identify practice variation and resistance trends. Where applicable, data triangulation validated qualitative insights against observable operational metrics.

Analytical methods included comparative clinical pathway mapping, sensitivity analysis of supply disruption scenarios, and stakeholder impact assessments to prioritize recommendations. Throughout the process, attention to data provenance, methodological transparency, and expert validation ensured that conclusions reflect clinical reality and operational feasibility.

Synthesis of Strategic Takeaways Emphasizing Clinical Imperatives, Operational Risks, and Opportunities for System-wide Improvement

This executive synthesis highlights a set of converging priorities: protect access to effective antimicrobials, accelerate diagnostic-driven therapy, and reinforce system-level resilience against supply and policy volatility. Clinically, the imperative is clear-prompt source control and tailored antimicrobial therapy save lives, but achieving this consistently requires investments in diagnostics, stewardship infrastructure, and cross-disciplinary coordination. Operationally, procurement and pharmacy leaders must anticipate supply chain shocks and maintain flexible strategies that safeguard critical agents without compromising clinical standards.

Strategically, the market environment rewards organizations that integrate diagnostics with therapeutic planning and that form durable partnerships with manufacturers and service providers to ensure supply reliability. Policy changes, including tariff adjustments and evolving regulatory expectations, will continue to create both risks and opportunities; responsive systems will be those that combine clinical rigor with agile contracting and contingency planning. Ultimately, translating insight into improved patient outcomes depends on aligning clinical pathways, stewardship goals, and procurement practices so that each reinforces the others in routine care and crisis response.

Leaders who operationalize these priorities will not only mitigate immediate risks but also contribute to broader efforts to preserve antimicrobial effectiveness and improve outcomes for patients with intra-abdominal infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intra-abdominal Infections Market, by Antibiotic Class

  • 8.1. Carbapenems
    • 8.1.1. Doripenem
    • 8.1.2. Ertapenem
    • 8.1.3. Imipenem/Cilastatin
    • 8.1.4. Meropenem
  • 8.2. Cephalosporins
    • 8.2.1. Fourth Generation
    • 8.2.2. Third Generation
      • 8.2.2.1. Cefotaxime
      • 8.2.2.2. Ceftriaxone
  • 8.3. Penicillins
    • 8.3.1. Ampicillin/Sulbactam
    • 8.3.2. Piperacillin/Tazobactam

9. Intra-abdominal Infections Market, by Infection Type

  • 9.1. Community Acquired
    • 9.1.1. Complicated
    • 9.1.2. Uncomplicated
  • 9.2. Hospital Acquired
    • 9.2.1. ICU Associated
    • 9.2.2. Post Surgical

10. Intra-abdominal Infections Market, by Pathogen Type

  • 10.1. Anaerobic
    • 10.1.1. Bacteroides Fragilis
    • 10.1.2. Clostridium Species
  • 10.2. Gram Negative
    • 10.2.1. Enterobacteriaceae
    • 10.2.2. Pseudomonas Aeruginosa
  • 10.3. Gram Positive
    • 10.3.1. Enterococcus Species
    • 10.3.2. Staphylococcus Aureus

11. Intra-abdominal Infections Market, by End User

  • 11.1. Ambulatory Care Centres
  • 11.2. Hospitals
    • 11.2.1. Secondary Care
    • 11.2.2. Tertiary Care

12. Intra-abdominal Infections Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intra-abdominal Infections Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intra-abdominal Infections Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Intra-abdominal Infections Market

16. China Intra-abdominal Infections Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bayer AG
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Eli Lilly and Company
  • 17.11. Gilead Sciences, Inc.
  • 17.12. GlaxoSmithKline plc
  • 17.13. Johnson & Johnson
  • 17.14. Merck & Co., Inc.
  • 17.15. Novartis AG
  • 17.16. Pfizer Inc.
  • 17.17. Roche Holding AG
  • 17.18. Sanofi S.A.
  • 17.19. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 257. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 258. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 260. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 294. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 296. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 299. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 302. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2032 (USD MILLION)
  • TABLE 303. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2032 (USD MILLION)
  • TABLE 305. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2032 (USD MILLION)
  • TABLE 306. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 309. NATO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. NATO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO INTRA-